We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 12.00 | 0.80% | 1,511.00 | 7,113,718 | 16:35:23 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,512.50 | 1,513.50 | 1,514.00 | 1,495.50 | 1,499.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 31.38B | 2.58B | 0.6211 | 24.37 | 62.15B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:22:53 | O | 2 | 1,506.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 14/3/2025 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 14/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 13/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 12/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 11/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 10/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 07/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 06/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 05/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
| 04/3/2025 | 07:00 | UK RNS | GSK PLC Transaction in Own Shares |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/3/2025 | 17:27 | Glaxosmithkline - The recovery | 34,185 |
| 12/3/2025 | 07:52 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 196 |
| 05/2/2025 | 08:59 | GSK | 74 |
| 10/10/2024 | 05:29 | GlazoSmithKline - News & Information | 148 |
| 17/4/2023 | 18:25 | Gsk zantac | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 17:41:08 | 1,506.50 | 2 | 30.13 | O |
| 17:31:28 | 1,507.00 | 1 | 15.07 | O |
| 17:30:19 | 1,511.00 | 433,584 | 6,551,454.24 | O |
| 17:16:28 | 1,505.41 | 328,356 | 4,943,104.06 | O |
| 17:06:08 | 1,505.50 | 3 | 45.17 | O |
| Top Posts |
|---|
Posted at 14/3/2025 08:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,499p.Gsk currently has 4,145,945,481 shares in issue. The market capitalisation of Gsk is £62,748,884,855. Gsk has a price to earnings ratio (PE ratio) of 24.37. This morning GSK shares opened at 1,499.50p |
Posted at 12/3/2025 10:53 by anhar Gary I was criticising the term "defensive" regarding capital performance as that is how it was being used. But of course it depends when you bought. For me, that performance has been pretty poor over the time held.Also, your math is wrong on the combined yield because the value of GSK is much higher than HLN. At present my GSK is worth roughly 3x my HLN so you can't use the simple arithmetic mean to arrive at the combined yield. Using simplified example figures, on £9,000 of GSK yielding 4% and £3,000 HLN at 1%, the combined holding is worth £12,000. The income would be GSK £360 and HLN £30, total £390. Thus the combined yield is 390/12,000 x 100 = 3.25%, ie. much nearer to GSK because of its heavier weighting in the pair. |
Posted at 14/2/2025 22:47 by pj84 Citadel building a short position won't have helped the share price recently.Ken Griffin’s Citadel bets £300mn against drugmaker GSK Hedge fund’s short position is the biggest in the FTSE 100 group in more than a decade. Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade. Billionaire Ken Griffin’s hedge fund disclosed that it had entered the net short position on Tuesday, with the bet worth 0.51 per cent of the company’s stock, according to data from the Financial Conduct Authority compiled by provider Breakout Point. The last time any firm disclosed a bet against the FTSE 100 pharmaceutical group was in 2013, according to the FCA disclosures. GSK’s shares have risen 11 per cent in the last month, as the drugmaker raised its long-term sales forecast and embarked on a rare £2bn stock buyback earlier this month. GSK reported better than expected earnings on strong sales of HIV and cancer drugs. But the stock has lagged rival pharmaceutical companies, as the drugmaker has failed to excite investors about its pipeline of new medicines and vaccines, which it needs to replace its HIV drugs when they face a patent cliff later in the decade. In the past five years, shares in GSK have fallen 15 per cent, compared with the S&P 500 pharmaceutical index, which rose 45 per cent. Emma Walmsley, GSK’s chief executive, has already faced a battle against an activist investor, when hedge fund Elliott Management built a multibillion-pound stake in the company in 2021. Elliott questioned whether Walmsley was the right leader for the company, given she does not have a scientific background. It also pushed for GSK to consider takeover offers for its consumer health business Haleon, which was later spun off. Analysts at JPMorgan said the fourth-quarter earnings and the company’s guidance for 2025 were “positive&rdqu GSK’s shares collapsed in August 2022 when lawsuits over the heartburn drug Zantac emerged. But when GSK settled the vast majority of cases for $2.2bn in October last year, the shares did not return to their previous level. The company has also suffered from unexpected bad news for two key products. In 2022, GSK withdrew its cancer drug Blenrep from the US market, after a trial did not meet FDA requirements for medicines that had received an accelerated approval. After further studies, the company is now expecting the drug will be reapproved by the regulator by July 2023. Sales of Arexvy, its vaccine for the respiratory syndical virus, known as RSV, dropped in the second half of last year because a US advisory panel unexpectedly recommended limiting its use. Citadel is the world’s top-performing hedge fund according to data from LCH Investments, an investor in hedge funds. The firm houses hundreds of trading teams who bet on a wide variety of assets including equities. Citadel manages $65bn worth of investor capital as of the start of the year, and was up 15.1 per cent in 2024. Citadel declined to comment as the firm does not discuss its positions. GSK did not immediately respond to a request for comment. |
Posted at 14/2/2025 11:08 by anhar I've had GSK in my income port since forever. Latest yield forecast at 1,436p on their predicted 2025 64p divi is about 4.5%. Not that high but acceptable so I'm staying in as I have for so long.Capital performance is dire, though I'm purely a long term hold income player, but for the record the share price has barely changed over all that time. The only reason I'm showing a modest profit on my combined GSK/HLN shares is the fine performance from Haleon, up about 55%, because I held on to my demerger allocation. HLN's yield is very low but my usual attitude to most events is to do nothing, which is really why I hung on. The income and capital value is small relative to the rest of the port so it makes little difference to total port income and valuation. |
Posted at 07/2/2025 18:12 by xtrmntr The market seemed reasonably pleased with pharmaceutical major GSK (GSK) after the company revealed a better than expected fourth quarter and an upgraded revenue forecast of up to 5 per cent for 2025, with core operating profits growth expected to be 6 to 8 per cent.The company also announced that it is to commence a £2bn share buyback programme that will be completed over the next 18 months. Overall, the results were a welcome tonic after months of steady share price falls. The year seems to have improved significantly as it progressed and GSK produced an operating margin in the fourth quarter of 29 per cent. Strength in its HIV and oncology portfolios was key to the results, offsetting weaknesses in vaccine sales as GSK generated £3bn in free cash flow. Oncology, which is a new area for the company, saw sales almost double at constant currency to £1.41bn.GSK's lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly contributed to the sustained share price fall in the second half of last year.The company noted that while vaccines sales were 4 per cent lower at £9.43bn, immunisation rates have improved year on year for many of its core products such as shingles vaccine Shingrix, sales of which were steady at £3.36bn, but with most of that growth coming outside the US. At just 8.9 times FactSet-compiled consensus forecasts for 2025, GSK is at near-decade lows in PE valuation terms and value investors looking for steady income may well be tempted. Buy. |
Posted at 07/2/2025 15:50 by dplewis1 THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "based on information available at the time and correspondence with regulators." GSK also stated that it was "continuing with investigations into the potential source of NDMA." Defendants also assured investors that "GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019." Finally, defendants claimed that they could not "quantify or reliably estimate the liability." These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market. WHAT'S NEXT? If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslr |
Posted at 05/2/2025 16:21 by geckotheglorious II commentGSK annual results get warm reception Trading at the bottom of a long-term trading range, these annual results have given the drug major a much-needed lift. ii's head of results explains why. GSK has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the group’s Vaccines business, which accounts for 29% of overall sales, have weighed heavily on GSK’s recent share price performance on a couple of fronts. Sales fell by 4% in 2024, as had been anticipated, with particular focus on the shingles vaccine Shingrix, which clawed back a deficit to post a gain of just 1%, and respiratory virus vaccine Arexvy, where sales declined by 51% on lower demand due to a limited recommendation from a US advisory committee. In addition, the nomination by President Trump of renowned vaccine sceptic Robert F Kennedy Jr cleared another hurdle yesterday, sending shares of Moderna Inc lower by 6.5% and adding broader weakness to the sector on the potential for both sentiment as well as fundamental concerns. Drug development is in any event a time-consuming, costly and risky endeavour, while there is also increasing evidence of litigation for the unintended side-effects of new products. Slowing some of the gains was the hope that the Food and Drug Administration will continue to be wholly responsible for approving the safety and efficiency of future drugs. However, GSK is far from being a one-trick pony, as evidenced by the performance of a Speciality Medicines unit which is the group’s largest, responsible for 38% of overall sales, where revenue growth of 19% to £11.8 billion provided some welcome relief. Feeding into the promising number were sales growth contributions of 13% from HIV to £7.1 billion, 13% to £3.3 billion for Respiratory/Immunolo The overall result was growth of 7% to £31.4 billion for group sales, marginally ahead of estimates, boosted by a fourth quarter contribution of £8.2 billion, comfortably ahead of the expected £7.8 billion. Immense cash generation of £8 billion and free cash flow of £3 billion showcased the group’s strength, enabling a reduction in net debt from £15 billion to £13 billion in the period. In addition, a share buyback programme of £2 billion was announced which should, all things being equal, support the share price as well as proving management confidence in prospects. Shareholder returns were further bolstered by a planned increase to the dividend which takes the projected yield to 4.6%, a clear attraction for followers of the stock. The shadow of litigation which follows the sector was also seen for GSK in the period, where operating profit fell by 33% in the 12 months ended 31 December to £4.02 billion, largely as a result of the settlement of £1.8 billion relating to its heartburn drug Zantac. Even so, this should now enable a line to be drawn since the vast majority of cases have been settled, and in any event the concerns had already been factored into the share price. More promisingly, GSK’s Research and Development efforts are continuing apace, with the current tally of 71 Speciality and Vaccines products in clinical development a promising sign of things to come. Of these, 19 are in Phase III, or late stage which is the final regulatory hurdle before the products get the full green light. GSK has also been making selective acquisitions over the period which heighten its expertise and focus over the suite of its products. The outlook is relatively upbeat, with turnover growth of between 3% and 5% expected next year, alongside core operating profit growth in the 6% to 8% range. The group’s more recent pipeline progress has also resulted in the sales outlook to 2031 being increased from more than £38 billion to over £40 billion. The shares have had a tumultuous time of late in navigating the actual and potential challenges, and have declined by 14% over the last year, as compared to a gain of 12.6% for the wider FTSE100. By the same token, a five year drop of 26% in the price also leaves the shares on an undemanding valuation in historic terms. Despite the warm reaction to the numbers in opening trade, it seems that a cure for all GSK’s ills may yet be a touch too early to call, with the market consensus of the shares as a hold likely to remain intact for the time being. |
Posted at 27/1/2025 09:20 by tradermichael Oxford University and pharmaceutical giant GSK are creating a new cancer vaccine to prevent the disease from developing.GSK and Oxford establish the GSK-Oxford Cancer Immuno Prevention Programme to advance novel cancer research • Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology • GSK to invest up to £50 million in collaboration to generate key insights on how cancer develops that could inform future development of cancer vaccines • Programme adds to existing relationship, including the ongoing GSK-Oxford Institute of Molecular and Computational Medicine |
Posted at 17/12/2024 13:58 by tradermichael GSK plc (LSE/NYSE: GSK), a global biopharmaceutical company, announced today that the European Medicines Agency (EMA) has granted its investigational drug, GSK'227, the Priority Medicines (PRIME) designation for the treatment of relapsed extensive-stage small-cell lung cancer (ES-SCLC). This regulatory acknowledgment is based on early clinical data suggesting potential therapeutic benefits in a disease marked by limited treatment options and poor patient outcomes.The PRIME designation is designed to expedite the development and review of drugs targeting unmet medical needs. GSK'227, an antibody-drug conjugate (ADC) targeting B7-H3, has shown promise in preliminary trials. It is the second major regulatory milestone for GSK'227, following the Breakthrough Therapy Designation it received from the US Food and Drug Administration in August 2024. Senior Vice President of Global Head Oncology at GSK, Hesham Abdullah, remarked on the significance of this development, noting the potential of GSK'227 to improve treatment for ES-SCLC and other tumor types with limited therapeutic options. The PRIME designation was supported by data from the ARTEMIS-001 study, an ongoing phase I trial conducted by Hansoh Pharma, which assessed the drug's safety and efficacy in over 200 patients with various advanced solid tumors. Lung cancer remains one of the leading causes of cancer-related deaths globally. In Europe alone, lung cancer accounted for an estimated 484,554 new cases and 375,784 deaths in 2022. ES-SCLC, a particularly aggressive form of lung cancer, often presents with widespread disease at diagnosis and has a high rate of relapse after initial treatment. |
Posted at 04/12/2024 10:32 by anhar If I were investing for capital growth then GSK which I've held for a very long time would be an utter crock. In fact the only reason my combined GSK/HLN holding is showing a small profit over my original cost of old GSK all those years ago is because HLN has boomed, up 51% on its allocated cost in the demerger, whilst new GSK is making a loss.But I'm not a growth player, I'm an income investor and usually hold long term so don't trade much. However the income situation is not too attractive either because the total income from GSK+HLN is well below the 80p old GSK was paying pre-demerger. And even that 80p had been frozen for several years. Not bad enough to dump but disappointing after decades. Still, that's the point of a diversified port where inevitably some sectors will do better than others but the essential trade-off is that risks are spread. |
Posted at 30/10/2024 18:53 by pj84 Positive update from HL"GSK: full-year guidance confirmed despite weak Q3 vaccine sales GSK beat Q3 earnings estimates due to growth in its specialty medicines. Written by Derren Nathan Head of Equity Research Oct 30, 2024 No recommendation Underlying operating profit rose by 5% to £2.8bn, driven by revenue growth and effective cost management. Underlying earnings per share also grew 5% to 49.7p, ahead of market forecasts of 43.5p. Free cash flow fell 20% to £1.3bn largely driven by the acquisition of rights to certain vaccine technologies. Net debt has fallen from £15.0bn to £12.8bn since the start of the year. GSK recognised a £1.8bn charge in relation to the Zantac settlement, with the ‘vast majority’ of cases now settled. With all full-year guidance unchanged, pointing to underlying operating profit growth in the 11-13% range. The third-quarter dividend rose from 14p to 15p. The shares were down 3.6% in early trading. Our view GSK’s on track to meet upgraded estimates despite ongoing weakness in it’s vaccine portfolio. Two key products, Arexvy and Shingrix were coming up against headwinds in the important US market. But both products still have the potential to reach new patient populations. The financial progress is underpinned by excellence in research & development that’s seen 11 positive late stage clinical updates so far this year, and is expected to yield five major product approvals next year. However, there can be no guarantee of continued success. Falling sales of COVID-19 medicines have held back growth but now that they are no longer material, comparatives are becoming less demanding. Beyond vaccines, the group also has a strong presence in HIV treatments which make up about 20% of total revenues. Its newer HIV treatments are a key part of GSK's future, as generic competitors eat away at pricing power for some of the group's legacy treatments. But the group focus for HIV is shifting to long-acting innovation therapies. And it’s these that have helped capture additional market share and drive double-digit growth for the category in the first half. Apretude is another important product to watch in the space. It’s the only approved medicine in its class and real-world studies have shown it to be 99% effective at preventing HIV infections. Cancer treatment, although relatively small in terms of current sales, is growing rapidly. Recent approvals and launches in new markets mean there are strong growth drivers for the existing portfolio. The development pipeline looks promising. Net debt has been coming down and currently sits at under 1.3x forecast cash profits, which we don't see as a major concern. The strong financial position and improving cash generation helps support a prospective dividend yield of 4.4%, but remember, no future payouts to shareholders can be assured. GSK's valuation is below the long-term average, and significantly less demanding than many of its peers. One reason it’s been held back was uncertainty over the financial impact of alleged cancer links to its heartburn drug Zantac. News that the majority of lawsuits relating to were being settled for $2.2bn materially de-risks the investment case. Looking ahead, strong execution of the growth strategy and clinical pipeline is likely to be the key focus for shareholders moving forward. So far so good, but remember, the drug approval process is long and expensive, with many treatments never seeing the light of day." HL forecast the forward PE of 8.6 with a forecast dividend yield of 4.4% |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
